Cargando…

Axitinib as a third or further line of treatment in renal cancer: a single institution experience

BACKGROUND: Kidney cancer is a lethal neoplasm that affects several thousands of people every year. Renal cell carcinoma (RCC) is the most common histologic type. Recent developments in the therapeutic approach include antiangiogenic targeted approaches and Immunotherapy. Thus, the therapeutic algor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsironis, G., Liontos, M., Kyriazoglou, A., Koutsoukos, K., Tsiara, A., Kaparelou, M., Zakopoulou, R., Cohen, A., Skafida, E., Fontara, S., Zagouri, F., Bamias, A., Dimopoulos, M. A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265645/ https://www.ncbi.nlm.nih.gov/pubmed/32487200 http://dx.doi.org/10.1186/s12894-020-00618-1

Ejemplares similares

Management of uterine sarcomas and prognostic indicators: real world data from a single-institution
por: Kyriazoglou, Anastasios, et al.
Publicado: (2018)

Retrospective analysis of bevacizumab-induced arthralgia and clinical outcomes in ovarian cancer patients. Single center experience
por: Kaparelou, Maria, et al.
Publicado: (2022)

CDK4/6 Inhibitors and Arthralgia: A Single Institution Experience
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)

Neutrophil-to-lymphocyte ratio and chemotherapy response score as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapy
por: Liontos, M., et al.
Publicado: (2021)

Germline and somatic variants in ovarian carcinoma: A next-generation sequencing (NGS) analysis
por: Andrikopoulou, Angeliki, et al.
Publicado: (2022)

Metastatic Hepatic Epithelioid Hemangioendothelioma Treated with Olaratumab: A Falling Star Rising?
por: Kyriazoglou, Anastasios, et al.
Publicado: (2020)

Secondary Alopecia Neoplastica Mimicking Alopecia Areata following Breast Cancer
por: Skafida, Efthymia, et al.
Publicado: (2020)

The emerging role of BET inhibitors in breast cancer
por: Andrikopoulou, A., et al.
Publicado: (2020)

SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint Inhibition
por: Terpos, Evangelos, et al.
Publicado: (2022)

Assessment of Postvaccination Neutralizing Antibodies Response against SARS-CoV-2 in Cancer Patients under Treatment with Targeted Agents
por: Zagouri, Flora, et al.
Publicado: (2022)

Ewing's sarcoma of the cervix: A case report of an unusual diagnosis in pregnancy treated with surgery, adjuvant VIDE and radiotherapy
por: Kyriazoglou, Anastasios, et al.
Publicado: (2019)

SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors
por: Zagouri, Flora, et al.
Publicado: (2021)

Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors
por: Liontos, Michalis, et al.
Publicado: (2021)

Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients
por: Liontos, Michalis, et al.
Publicado: (2021)

Circulating tumor DNA-based predictive biomarkers in breast cancer clinical trials: a narrative review
por: Fiste, Oraianthi, et al.
Publicado: (2020)

Metaplastic Carcinoma of the Breast: Case Series of a Single Institute and Review of the Literature
por: Papatheodoridi, Alkistis, et al.
Publicado: (2023)

Prognostic role of microRNAs in breast cancer: A systematic review
por: Zografos, Eleni, et al.
Publicado: (2019)

How we treat endocrine complications of immune checkpoint inhibitors
por: Paschou, S.A., et al.
Publicado: (2021)

Olaratumab administered in two cases of phyllodes tumour of the breast: end of the beginning?
por: Kyriazoglou, Anastasios, et al.
Publicado: (2019)

What Has Changed in the Management of Uterine Serous Carcinomas? Two Decades of Experience
por: Liontos, Michalis, et al.
Publicado: (2021)

Optimal Time Interval between Neoadjuvant Platinum-Based Chemotherapy and Interval Debulking Surgery in High-Grade Serous Ovarian Cancer
por: Andrikopoulou, Angeliki, et al.
Publicado: (2023)

“The emerging role of capivasertib in breast cancer”
por: Andrikopoulou, Angeliki, et al.
Publicado: (2022)

Clinical Perspectives of ERCC1 in Bladder Cancer
por: Koutsoukos, Konstantinos, et al.
Publicado: (2020)

Chemotherapy resumption in ovarian cancer patient diagnosed with COVID-19
por: Liontos, Michalis, et al.
Publicado: (2020)

The Mutational Landscape of Early-Onset Breast Cancer: A Next-Generation Sequencing Analysis
por: Andrikopoulou, Angeliki, et al.
Publicado: (2022)

DNA Damage Repair: Predictor of Platinum Efficacy in Ovarian Cancer?
por: Stefanou, Dimitra T., et al.
Publicado: (2021)

Multi-Gene Mutation Profiling by Targeted Next-Generation Sequencing in Premenopausal Breast Cancer
por: Zografos, Eleni, et al.
Publicado: (2022)

77P The impact of COVID-19 on gynecological cancer diagnoses in Greece
por: Fiste, O., et al.
Publicado: (2023)

The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma
por: Fiste, Oraianthi, et al.
Publicado: (2021)

Risk for Arterial Thromboembolic Events (ATEs) in Patients with Advanced Urinary Tract Cancer (aUTC) Treated with First-Line Chemotherapy: Single-Center, Observational Study
por: Bamias, Aristotelis, et al.
Publicado: (2022)

BRCA1/2 Mutation Types Do Not Affect Prognosis in Ovarian Cancer Patients
por: Liontos, Michalis, et al.
Publicado: (2021)

MicroRNAs as Potential Predictors of Response to CDK4/6 Inhibitor Treatment
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)

Oncological Patients With Endocrine Complications After Immunotherapy With Checkpoint Inhibitors Present Longer Progression-Free and Overall Survival
por: Paschou, Stavroula A., et al.
Publicado: (2022)

Management of the Elderly Patients with High-Grade Serous Ovarian Cancer in the REAL-WORLD Setting
por: Liontos, Michalis, et al.
Publicado: (2021)

Profile of trebananib (AMG386) and its potential in the treatment of ovarian cancer
por: Liontos, Michalis, et al.
Publicado: (2014)

Advances in Gynecological Cancers
por: Liontos, Michalis, et al.
Publicado: (2022)

Continuing Cancer Therapy through the Pandemic While Protecting Our Patients: Results of the Implementation of Preventive Strategies in a Referral Oncology Unit
por: Liontos, Michalis, et al.
Publicado: (2021)

Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors
por: Terpos, Evangelos, et al.
Publicado: (2021)

Treating bladder adenocarcinoma
por: Tsironis, Georgios, et al.
Publicado: (2018)

Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ilj8r8nrc347u70reh3j7n6t3e